Exscientia PLC on Monday said it plans to sell nearly 13.1 million American depositary shares at between $20 and $22 apiece in its initial public offering.
At the $21 midpoint of that range, the Oxford, U.K., clinical-stage pharmatech company said it expects net proceeds of about $249.2 million, or roughly $287.6 million if the underwriters exercise an option to buy an additional 1.96 million ADSs.
Exscientia said it also expects to net about $151.3 million from concurrent private placements of $125 million with an affiliate of SoftBank Group Corp. and $35 million with the Bill & Melinda Gates Foundation.
Exscientia, which is using artificial intelligence to design patient-based drugs, said it believes the proceeds from the IPO and private placements, coupled with its existing resources, will be sufficient to fund its operations and capital-spending needs for at least a year.
Each Exscientia represents one ordinary share. In a filing with the U.S. Securities and Exchange Commission, Exscientia said it would have about 119.9 million shares outstanding after the IPO and private placements, assuming exercise of the overallotment option, for a market capitalization topping $2.5 billion at the $21-a-share pricing midpoint.
Exscientia said it has applied to list its ADSs on the Nasdaq Global Select Market under the symbol EXAI.
关注我们